Damora TherapeuticsDMRA
13F holders, Q2 2026 (June 30)3holders
$26.01avg. 13F price*
At the end of Q2 2026, 3 institutions reported holding Damora Therapeutics Inc. (DMRA) in their 13F filings. The largest holders were T. Rowe Price Associates Inc. ($1.3M), Harbour Investments, Inc. ($1K) and Rothschild Investment LLC ($884).
- Company
- Damora Therapeutics Inc.
- CUSIP
- G2646Y104
- Latest filing quarter
- Q2 2026
Total Exit/New Position Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $1.3M |
| Exits | 0 | $0 |
Ownership 3 holders
| T. Rowe Price Associates Inc. | 0.00% | New | 48,743 | $1.3M |
| Harbour Investments, Inc. | 0.00% | New | 40 | $1K |
| Rothschild Investment LLC | 0.00% | New | 34 | $884 |
"% of holder's portfolio" is DMRA's weight in each manager's 13F, not the share of Damora Therapeutics Inc. the manager owns.